Dual-Ended Antibody Treatment Against Ovarian Cancer

Antibody treatment involves using proteins called antibodies, designed to recognize and destroy cancer cells, as a type of immunotherapy. Recently, particularly with advances in immunotherapy, studies developing antibody treatments against various cancer types have increased. In August 2018, Cancer Cell published a study in which, in ovarian cancer cells, an antibody targeting two different proteins simultaneously was developed (dual-specificity targeting).
Previous studies have demonstrated the success of antibody treatments in ovarian cancer and other solid (non-blood) tumors. However, important factors limit treatment effectiveness. The tumor microenvironmentcontains cells whose presence prevents antibodies from reaching cancer cells. This study developed a new dual-action antibody to cross the tumor microenvironment barrier as its approach.
This dual-ended antibody targets two different proteins in ovarian cancer. One end targets folate receptor alpha 1 (FOLR1), a protein with high activity in ovarian cancer. The antibody's other end binds to death receptor 5 and causes cell death. Thus a single antibody works both by recognizing the cancer cell and by initiating its death mechanism.
Tests of the developed antibodies in laboratory animals found that; dual-ended antibodies were 100 times more effective than other antibodies as a finding.
What Does This Study Mean for Us?
- Antibody treatments use antibodies engineered through genetic techniques to target cancer cells. They are therefore called targeted treatments. This study developed a dual-ended antibody to target ovarian cancer effectively.
- Ovarian cancers have developed an important resistance mechanism against antibody treatments. Low oxygen levels in the tumor microenvironment prevent immune cells from surviving and functioning normally. New antibodies may overcome this barrier.
- The newly developed antibodies may also help reduce adverse effects. Many current antibodies rapidly leave the bloodstream, accumulate in the liver and cause toxicity (adverse effects). The new cancer-specific antibodies offer "targeted" cancer treatment by targeting only cancer cells.
Sources
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.
Cancer Cell, 13 August 2018.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.